BRIEF-AstraZeneca’s lung cancer drug receives full EU approval

AstraZeneca Plc:

* Tagrisso receives full approval in the EU

* European Commission has granted full marketing authorisation for Tagrisso (osimertinib)

* Grant for treatment of adults with locally-advanced or metastatic epidermal growth factor receptor T790m mutation-positive non-small cell lung cancer

* In March 2017, US Food and Drug Administration granted Tagrisso a conversion from accelerated to full approval

* Warnings and precautions include interstitial lung disease (ILD), keratitis, left ventricular ejection fraction (LVEF) and QTC interval prolongation Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

News Source:


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s